Medical Affairs and Regulatory Affairs

Diseases classified as rare (orphan) are those with a very low prevalence. Children are disproportionately affected by rare or orphan diseases, which are frequently inherited. Many of these diseases are incurable and have terrible consequences for individuals and their families. Patients and health-care systems alike face numerous challenges as a result of rare diseases. They are rarely explored since they are unusual, and there is less understanding about the condition and fewer doctors who specialise in it. Furthermore, because most diseases do not have a specific therapy, diagnosis is not necessary. Patients must get safe and effective treatments, according to regulatory standards for drug approval for rare diseases. The challenge for regulators, patient groups, pharmaceutical companies, politicians, and payers is to ensure that novel therapies are available to everyone, regardless of nationality or economic status. Despite improvements, there is still a need for investment in the field of rare diseases. There is no financial incentive for industry to invest in discovering medicines for rare diseases because the market potential is small. All of this prompted patients, researchers, and governments all over the world to pass a bill encouraging and incentivizing researchers and the pharmaceutical industry to produce scientific and clinical understanding, as well as potential remedies, for these disorders.